Design Therapeutics, Inc. (DSGN) stock
DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.84−0.08 (-0.81%)
Close on Nov 17, 2026Market cap $615.80MP/E –Yield –
Earnings
Design Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 8, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.32
-$0.30 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Design Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 8, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | – | – | -$0.32 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 3, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 28, 2026during market hours | – | – | -$0.29 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 9, 2026during market hours | – | – | -$0.27 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025during market hours | – | – | -$0.30 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025during market hours | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025during market hours | – | – | -$0.31 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 10, 2025before the open | – | – | -$0.24 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 5, 2024before the open | – | – | -$0.21 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024during market hours | – | – | -$0.20 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 19, 2024during market hours | – | – | -$0.21 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023during market hours | – | – | -$0.28 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023during market hours | – | – | -$0.36 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023during market hours | – | – | -$0.35 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 14, 2023during market hours | – | – | -$0.31 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022during market hours | – | – | -$0.32 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022during market hours | – | – | -$0.27 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022during market hours | – | – | -$0.24 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 10, 2022during market hours | – | – | -$0.20 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021during market hours | – | – | -$0.21 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 9, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 10, 2021during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Design Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Design Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Design Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
See a number that looks wrong?